Relapsing and progressive MS: the sex-specific perspective
- PMID: 33029201
- PMCID: PMC7521047
- DOI: 10.1177/1756286420956495
Relapsing and progressive MS: the sex-specific perspective
Abstract
Background: Multiple sclerosis (MS) is an inflammatory and neurodegenerative disease whose aetiology is not fully understood. The female sex is clearly predominant, with a sex ratio between 2 and 3. In primary progressive MS the sex ratio almost balances out. Since the age at onset is higher for patients with progressive onset (POMS) than for relapsing onset (ROMS), it can be hypothesized that the age at onset is a decisive factor for the sex ratio.
Methods: To address this aspect, we compare clinical and demographic data between females and males for the different disease courses within the population of the German MS Register by the German MS Society. Only patients with complete details in mandatory data items and a follow-up visit since 01. Jan 2018 were included.
Results: A total of 18,728 patients were included in our analyses, revealing a female-to-male ratio of 2.6 (2.7 for patients with ROMS and 1.3 for POMS). The age at diagnosis is higher in patients with POMS (43.3 and 42.3 years for females and males versus 32.1 and 33.2 years, respectively). Females irrespective of disease course are statistically significantly more often affected by cognitive impairment (POMS: p = 0.013, ROMS: p = 0.001) and depression (POMS: p = 0.002, ROMS: 0.001) and suffer more often from pain (POMS and ROMS: p < 0.001). Fatigue is significantly more often seen in females with ROMS (p < 0.001) but not in POMS. Females with ROMS retire significantly (p < 0.001) earlier (42.8 versus 44.2 years) and to a greater extent than males (28 versus 24%). Disease progression was similar for women and men.
Conclusion: Our analysis shows that clinical and demographic data differ more between disease courses than between men and women. For pain, depression and cognitive impairment the female sex is the decisive factor. Whether these factors are responsible for the earlier retirement of females with ROMS is not clear. Appropriate measures for optimization of symptomatic treatment as well as to promote employment should be taken.
Keywords: age of onset; multiple sclerosis; progressive MS; relapsing MS; sex ratio.
© The Author(s), 2020.
Conflict of interest statement
Conflict of interest statement: PSR received research grants from Biogen, Merck, Roche; consultancy or speaker fees from Almirall, Biogen, Celgene, Merck, Roche, Novartis, Sanofi Genzyme, Sandoz. None of them resulted in a conflict of interest regarding the submitted work. DE declares no conflict of interest. KH has received speakingfees, travel support, and research honoraria from Biogen,Teva, Sanofi-Genzyme, Novartis, Bayer Healthcare, MerckSerono, and Roche. None resulted in a conflict of interest. JH declares no conflict of interest to the submitted work. DP received research grants from Sandoz, Schering, Biogen; speaker fees from Almirall, Bayer, Biogen, Merck, Novartis, Roche, Sanofi Genzyme and Teva. None of them resulted in a conflict of interest regarding the submitted manuscript. Alexander Stahmann reports institutional Grants for the enhancement of the German MS-Register by Biogen, Celgene, Merck and Novartis, all outside this study. UKZ received speaker fees from Alexion, Almirall, Bayer, Biogen, Merck, Novartis, Roche, Sanofi Genzyme and Teva. None of them resulted in a conflict of interest regarding the submitted manuscript.
Figures
Similar articles
-
Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies.J Neurol. 2024 Jan;271(1):472-485. doi: 10.1007/s00415-023-11980-z. Epub 2023 Sep 28. J Neurol. 2024. PMID: 37768389 Free PMC article.
-
Long-term Cognitive Outcomes in Patients With Pediatric-Onset vs Adult-Onset Multiple Sclerosis.JAMA Neurol. 2019 Sep 1;76(9):1028-1034. doi: 10.1001/jamaneurol.2019.1546. JAMA Neurol. 2019. PMID: 31206130 Free PMC article.
-
Long-term Socioeconomic Outcomes Associated With Pediatric-Onset Multiple Sclerosis.JAMA Neurol. 2021 Apr 1;78(4):478-482. doi: 10.1001/jamaneurol.2020.5520. JAMA Neurol. 2021. PMID: 33616605 Free PMC article.
-
Rituximab for relapsing-remitting multiple sclerosis.Cochrane Database Syst Rev. 2013 Dec 6;(12):CD009130. doi: 10.1002/14651858.CD009130.pub3. Cochrane Database Syst Rev. 2013. PMID: 24310855 Review.
-
Aging in multiple sclerosis: from childhood to old age, etiopathogenesis, and unmet needs: a narrative review.Front Neurol. 2023 Jun 2;14:1207617. doi: 10.3389/fneur.2023.1207617. eCollection 2023. Front Neurol. 2023. PMID: 37332984 Free PMC article. Review.
Cited by
-
Impact of menopause on relapse rate and disability level in patients with multiple sclerosis (MS): a systematic review and meta-analysis.BMC Neurol. 2023 Sep 4;23(1):316. doi: 10.1186/s12883-023-03332-1. BMC Neurol. 2023. PMID: 37667181 Free PMC article.
-
miRNA Signature in CSF From Patients With Primary Progressive Multiple Sclerosis.Neurol Neuroimmunol Neuroinflamm. 2022 Dec 9;10(1):e200069. doi: 10.1212/NXI.0000000000200069. Print 2023 Jan. Neurol Neuroimmunol Neuroinflamm. 2022. PMID: 36724195 Free PMC article.
-
Genetic risk variants for multiple sclerosis are linked to differences in alternative pre-mRNA splicing.Front Immunol. 2022 Oct 28;13:931831. doi: 10.3389/fimmu.2022.931831. eCollection 2022. Front Immunol. 2022. PMID: 36405756 Free PMC article.
-
Immunosenescence in Neurological Diseases-Is There Enough Evidence?Biomedicines. 2022 Nov 9;10(11):2864. doi: 10.3390/biomedicines10112864. Biomedicines. 2022. PMID: 36359383 Free PMC article. Review.
-
Genetic, Environmental and Lifestyle Determinants of Accelerated Telomere Attrition as Contributors to Risk and Severity of Multiple Sclerosis.Biomolecules. 2021 Oct 13;11(10):1510. doi: 10.3390/biom11101510. Biomolecules. 2021. PMID: 34680143 Free PMC article. Review.
References
LinkOut - more resources
Full Text Sources
